Updated Jul 16, 2026
KOZARICH JOHN W has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.18M.

John W. Kozarich is a corporate director known for his role at Ligand Pharmaceuticals Inc., where he has served as a director. He has participated in multiple SEC filings, indicating his involvement in the company's governance.
| Role | Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-09 | LGND | LIGAND PHARMACEUTICALS INC | A — Grant or award | 836 | $0.00 | |
| 2026-05-15 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale | 1.6K | $223.50 | $352K |
| 2026-05-15 | LGND | LIGAND PHARMACEUTICALS INC | M — Option exercise | 1.6K | $69.51 | $109K |
| 2026-05-15 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale | 459 | $224.00 | $103K |
| 2026-05-15 | LGND | LIGAND PHARMACEUTICALS INC | M — Option exercise | 459 | $69.51 | $32K |
| 2026-05-15 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale | 116 | $234.09 | $27K |
| 2026-05-15 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale | 105 | $232.57 | $24K |
| 2026-05-15 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale | 165 | $231.87 | $38K |
| 2026-05-15 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale | 1 | $229.87 | $230 |
| 2026-05-15 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale | 80 | $227.37 | $18K |
| 2026-04-02 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 159 | $204.26 | $32K |
| 2026-04-02 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 43 | $202.91 | $9K |
| 2026-04-02 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 79 | $202.42 | $16K |
| 2026-04-02 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 40 | $201.24 | $8K |
| 2026-04-02 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 146 | $199.97 | $29K |
| 2026-03-05 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 42 | $203.57 | $9K |
| 2026-03-05 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 50 | $202.54 | $10K |
| 2026-03-05 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 83 | $201.65 | $17K |
| 2026-03-05 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 41 | $200.40 | $8K |
| 2026-03-05 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 204 | $199.69 | $41K |
John W. Kozarich is a corporate director known for his role at Ligand Pharmaceuticals Inc., where he has served as a director. He has participated in multiple SEC filings, indicating his involvement in the company's governance.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 32 open-market sales ($1.18M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live KOZARICH JOHN W profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.